Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06395883 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease

Study acronym: BOOGIE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 3 months later Jun 2026 → Oct 2027
See other at-risk trials from Diakonhjemmet Hospital

Record History

  1. Primary completion pushed from Jun 2026 to Oct 2027v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2024 to Jan 1, 2025
    • Primary completion date: Dec 2025 to Jun 2026
    • Study completion date: Jun 2028 to Dec 2028
    v3
  3. Start date: Aug 2024 to Sep 2024
    • Secondary endpoints: details revised at 3 of 3 entries
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment. There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.
Trial Details
NCT Number NCT06395883
Lead Sponsor Diakonhjemmet Hospital
Collaborators: Vestre Viken Hospital Trust, Hormone Laboratory, Aker University Hospital, Oslo, Norway
Conditions
(from sponsor)		 Osteoporosis, Osteoporosis, Steroid Induced, Inflammatory Rheumatism
Related terms Osteoporosis, Rheumatic Fever
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov